8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported) – February 8, 2011

WEST PHARMACEUTICAL SERVICES INC.

(Exact name of registrant as specified in its charter)

Pennsylvania	1-8036	23-1210010
(State or other jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
101 Gordon Drive, PO Box 645, Lionville, PA		19341-0645
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: 610-594-2900

Not Applicable

(Former name or address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  

Item 7.01. Regulation FD Disclosure

On February 8, 2011, Donald E. Morel, Jr., Ph.D., our Chairman and Chief Executive Officer will present at the UBS 21st Global Healthcare Services Conference in New York, NY at 1:00 p.m. Eastern Time.

A copy of the Company’s presentation materials from the conference will be available for 30 days through the Investors link at the Company’s website, http://www.westpharma.com, and is also attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (Exchange Act) or otherwise subject to the liabilities of that section, nor will it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific referencing in such filing.

Item 9.01.  Financial Statements and Exhibits

(d)	Exhibits
	Exhibit 99.1	West Pharmaceutical Services, Inc. Overview (Investor Presentation).

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

WEST PHARMACEUTICAL SERVICES, INC.

/s/ John R. Gailey III

John R. Gailey III, Vice President, General

Counsel and Secretary

February 8, 2011

3

EXHIBIT INDEX

Exhibit No.	Description
99.1	West Pharmaceutical Services, Inc. Overview (Investor Presentation).

4

EX-99.1

WEST PHARMACEUTICAL SERVICES OVERVIEW

Solutions for Injectable Drug DeliveryNYSE:WSTwww.westpharma.com

UBS

21st Global Healthcare Services Conference

New York, NY February 8, 2011

This presentation contains “forward-looking statements”, as that term is defined in the Private
Securities Litigation Reform Act of 1995, that are based on management’s beliefs and
assumptions, current expectations, estimates and forecasts.Statements that are not
historical facts, including statements that are preceded by, followed by, or that include, words
such as “estimate,” “expect,” “intend,” “believe,” “plan,” “anticipate” and other words and terms
of similar meaning are forward-looking statements.West’s estimated or anticipated future
results, product performance or other non-historical facts are forward-looking and reflect our
current perspective on existing trends and information.

Many of the factors that will determine the Company’s future results are beyond the ability of
the Company to control or predict.These statements are subject to known or unknown risks
or uncertainties, and therefore, actual results could differ materially from past results and
those expressed or implied in any forward-looking statement.You should bear this in mind as
you consider forward-looking statements. A non-exclusive list of important factors that may
affect future results may be found in West’s filings with the Securities and Exchange
Commission, including our annual report on Form 10-K and our periodic reports on Form 10-
Q and Form 8-K. You should evaluate any statement in light of these important factors.

Safe Harbor Statement

2

West is a globally diversified manufacturer of products consumed in the healthcare and
consumer markets.

Every day over 80 million components manufactured by West, and our partner Daikyo, are
used to enhance the quality of healthcare worldwide.

3

A Diverse, Stable Customer Base

Pharmaceutical/Biotech

Generic

Medical Device

4

Sales and Income from
Continuing Operations
($ in millions)

5

2010 Segment Reorganization

Packaging Systems

•Established leadership

•High market share

•Stable growth rate

Delivery Systems

•Proprietary devices

•Contract manufacturing

•High projected growth rate

Development

Primary Package

Administration

6

Pharmaceutical Packaging Systems

West MixJect®
and Vial2Bag®

Prefilled Glass
Cartridge and
Pen

Glass
Vials
and
Syringes

7

Delivery Systems

West
ConfiDose®
Auto-injector
System

West
Electronic
Patch-injector

8

Daikyo Crystal Zenith® is a registered trademark of Daikyo, Seiko, Ltd.

2010 Issues

•General Operating Challenges:

–Pharma M&A continued

–Impact of healthcare reform uncertainty

–Currency volatility; commodity price fluctuations

–Changes in customer order patterns and inventory policies

–Operations restructuring announced in Q4

–Non-recurring 2009 H1N1 Sales

•No Update on 2010 Fourth Quarter or Full-Year Results

•2010 Year-End Call: February 17, 2011, 9:00 A.M.

9

2011 Market Trends

•Asymmetric global economic recovery

–Europe, US, Japan remain sluggish

–China, India, Brazil stronger

–Continuing Fx, commodity price volatility

•More demanding regulatory environment

–Bydureon

–Benlysta

–Changes to approved indications (Avastin)

•Broader trends in Pharma/Device markets continue:

–Thin near term pipelines

–Pharma M&A - shift to large molecules

–Increased manufacturing outsourcing (India generic growth)

10

•Pharmaceutical Packaging Segment

–Demographics and increasing prevalence of chronic disease

–Biologics

–Growth in Emerging Markets

–Increased access to Healthcare

–Escalating quality expectations: “Zero Defects”

•Delivery Systems Segment

–Demand for combination products that promote safety, dosing accuracy,
ease of use, and deliver cost savings

–Drug product life cycle management

–Glass compatibility/breakage issues

What will Drive Future Growth?

11

Category	Key Customers	Projected Growth
Diabetes		> 10 %
Oncology		> 10 %
Vaccines		> 10 %
Autoimmune		>8%

IMS April 2010 Report; Business Insights 2009; GBI Research 2009

12

Therapeutic Category Growth Drivers

•Packaging Systems Segment

–Grow incremental value per unit

–Geographic expansion - capacity investments in Asia

–Improved operating efficiency: lean operations

–Strategic acquisitions and partnerships

•Delivery Systems Segment

–Commercialize CZ opportunities

–Develop new platform opportunities - combination products

Growth Strategy

13

Value Proposition

Proprietary
Products

Revenue and
Margin
Opportunity

Disposable Device
Components

Westar®RS

Mix2Vial®

Westar® RU

Standard
Components

Consumer
Products

Packaging

Delivery

14

Faster Growth of High-Value Products
Pharmaceutical Packaging Systems

15

Drivers for Pharma Industry Life Cycle
Management

•To maximize the value of the drug development program

–Extend the value of the molecule as an asset

•Delivery systems as drug formulation life cycle management

–Generate more revenue per dose

•To expand or retain market share in a competitive
environment

–Reduce preparation and administration time

–Improve patient compliance

–Ease of use for self administration

–Accurate delivery of dosage

16

Pharma Industry Drug Life Cycle Management

Phase I

Phase II

Phase III

Post-Market Life Cycle Management

8 - 10 years

2 - 3 years

2 - 3 years

Regulatory

Approval

Discovery

17

Ready Pack™ System

Utilizes West’s proprietary

FluroTec® technology

FluroTec® technology is licensed from Daikyo Seiko, Ltd.

18

RU Vials

RU Seals

Glass

NovaPure™

Utilizes West’s
proprietary

FluroTec® technology

CZ®

Daikyo Resin CZ®

Utilizes Daikyo’s
proprietary

Crystal Zenith
technology

FluroTec® technology is licensed from Daikyo Seiko, Ltd.

Daikyo Crystal Zenith® is a registered trademark of Daikyo, Seiko, Ltd.

19

Mix2Vial®

Utilizes Medimop’s
proprietary
technologies

Vial Adapters

Utilizes Medimop’s
proprietary
technologies

Ready Pack™ System

Utilizes West’s proprietary

FluroTec® technology

FluroTec® technology is licensed from Daikyo Seiko, Ltd.

20

Luer Lock Glass Syringe

PFS Plungers

Utilizes West’s
proprietary

FluroTec®
technology

Westar® RU
Plungers in Port Bag

Utilizes West’s proprietary
FluroTec® technology

RU CZ® Insert
Needle Syringe

Utilizes Daikyo’s
proprietary Crystal
Zenith® technology

FluroTec® technology is licensed from Daikyo Seiko, Ltd.

Daikyo Crystal Zenith® is a registered trademark of Daikyo, Seiko, Ltd.

21

Syringe with NovaGuard™
Passive Safety Needle

Utilizes West’s proprietary
technology

ConfiDose™ Auto Injector

Utilizes West’s proprietary
technology

22

Concerns With Glass Syringes

•Interaction with sensitive biologics

•Protein aggregation (silicone oil)

•Residual chemicals (tungsten, glue)

•Glass flakes

•Breakage

•In process

•Within auto-injector systems

•Recent FDA recalls

•Dimensional variation

•Breakage in auto-injector systems

•Designed for manual injection

•Variable silicone distribution

•Amount of silicone coverage

•Age of barrel

•Inconsistent break force and
sustaining-force

•Quality

•Cosmetic defects

•High levels of inspection necessary

•High “cost of quality”

Siliconized Glass Syringe

Crystal Zenith Syringe

23

2010 Glass-related Recalls

24

Electronic Patch Injector System

•Controlled, subcutaneous, micro-
infusion delivery of high volumes
and high viscosity drugs

•Prefilled cartridge, no need for
user filling

•Based on Daikyo CZ cartridge

•Compact

•Hidden needle for safety

•Single push-button operation

•Fully programmable

25

Prototype Electronic Patch Injector Operation

Programmed by PDA or PC

Dose may be customized

Attached and activated by patient

26

Custom Delivery Device Utilizing Daikyo CZ® Resin

Utilizes Daikyo’s proprietary Crystal Zenith technology

Daikyo Crystal Zenith® is a registered trademark of Daikyo, Seiko, Ltd.

27

West’s Strategy Drives Revenue
Growth in Excess of Unit Growth

Lyo Mixing Station

Launched 1998

Lyo Vial Adapter

Launched in 2003

Prefilled Syringe

Launched in 2004

General trend for level of device

features and functionality

US Sales by Device for 2007*

(One year after Autoinjector launch)

* Data source IMS Health

Taken from presentation at Management Forum Annual Conference in London (March 22 & 23, 2010), Don Rogers, Genentech

Prefilled Auto Injector

Launched in 2006

28

Long-Term Growth Opportunity

Strategic Planning Goals:

•Projected 2014 sales of $0.6 billion

•Projected 2014 Operating margin: > 20%

$1.5 billion market for components with unit
growth 0% to 8% per year, depending on
product and therapeutic segment

Strategic Planning Goals:

•Projected 2014 sales of $1.0 billion

•Projected 2014 Operating margin: > 20%

Pharmaceutical

Packaging Systems

Primary Container Solutions

Pharmaceutical Delivery
Systems

Administration Systems

Consolidated 2014 Planning Objectives

•2014 Sales: $1.6 billion

•2014 Operating Margin: 19%

29

Our Long-Term Focus

•Pharmaceutical Packaging Systems

–Organic growth (on average) of 3-5% per year

–Margin expansion through operating efficiency, product mix

–Capital investments targeted at enhanced quality and value

•Pharmaceutical Delivery Systems

–Deliver the potential of Daikyo CZ products

–Increase healthcare-consumable contract manufacturing revenue

–Grow proprietary safety and delivery system businesses

•Financial discipline

–Operating cash flow: Discretionary SG&A, R&D and capital spending that
are supported by revenue growth

–Deliver returns on invested capital (“ROIC”) that regularly exceed weighted
average cost of capital (“WACC”)

–Align incentives with financial performance and value creation

30

Summary

•Well positioned

–Substantial market share

–Proprietary technology

–Diversified customer base

–Global footprint

•Stability with growth potential

–Strength in new product pipeline

–Preferred products for biologics

•The financial strength to invest

–Reliable operating cash flow

–Balance sheet strength

•2010 Year-end call

–February 17, 2011 - 9:00AM

Injectable Container Solutions

Advanced
Injection
Systems

Prefillable Syringe Systems

Safety and Administration
Systems

31

WEST PHARMACEUTICAL SERVICES

Solutions for Injectable Drug DeliveryNYSE:WSTwww.westpharma.com

32